Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

FDA Drug Safety Podcasts

Innehåll tillhandahållet av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

3+ y ago 3:00

MP3•Episod hem

Listen to FDA Drug Safety Podcast on due to risk of serious liver injury, FDA restricts use of Ocaliva in primary biliary cholangitis (PBC) patients with advanced cirrhosis

62 episoder

#Science #Fitness #Biology #Medicine #Government #Center For Drug Evaluation #Drug Administration #U.S. Food

Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

FDA Drug Safety Podcasts

0-10 subscribers

published 3+ y ago

Dela

MP3•Episod hem

Listen to FDA Drug Safety Podcast on due to risk of serious liver injury, FDA restricts use of Ocaliva in primary biliary cholangitis (PBC) patients with advanced cirrhosis

62 episoder

#Science #Fitness #Biology #Medicine #Government #Center For Drug Evaluation #Drug Administration #U.S. Food

Alla avsnitt

Välkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

Lyssna på 500+ ämnen

Liknande FDA Drug Safety Podcasts

Podcaster värda att lyssna på

FDA Drug Safety Podcasts « » Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

Podcaster värda att lyssna på

Välkommen till Player FM

Liknande FDA Drug Safety Podcasts

Snabbguide

FDA Drug Safety Podcasts « »
Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis